A Quiet Pause in Your Daily Ritual. /We test things over months, not afternoons. /2026.10.13
FAQ RSS 검색 뉴스레터 →
Where modern culture meets mindful insight Skin · Wellness · Living · Table · Notes · Abroad
Monthly Glow
⌕
Subscribe
The Ritual·Editor's Pick·Latest
Ingredient Notes Living·5 min read

엔비디아·릴리, AI 신약 개발 공동혁신 랩 출범

SoyulEditor · 2026.02.27
구독하기 →

무슨 발표인가

  • 5년간 최대 $10억 투자 규모
  • 캘리포니아 베이에어리어 소재
  • 생물학·의학 전문가와 AI 엔지니어 협업

5년, 최대 10억 달러, 캘리포니아

원문 (영어)

News Summary: NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to address the hardest problems in drug discovery. The co-innovation lab infrastructure will be built on the NVIDIA BioNeMo platform and the NVIDIA Vera Rubin architecture.

NVIDIA and Lilly will pioneer robotics and physical AI to accelerate and scale medicine discovery and production. J.P. Morgan Healthcare Conference —NVIDIA and Eli Lilly and Company today announced a first-of-its-kind AI co-innovation lab focused on applying AI to tackle some of the most enduring challenges in the pharmaceutical industry.

The lab brings together Lilly’s world-leading expertise in discovering, developing and manufacturing medicines with NVIDIA’s leadership in AI, accelerated computing and AI infrastructure. The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new AI co-innovation lab.

Based in the San Francisco Bay Area, the lab will co-locate Lilly domain experts in biology, science and medicine with top AI model builders and engineers from NVIDIA, allowing them to work side by side to generate large-scale data and build powerful AI models that can accelerate medicine development, using NVIDIA BioNeMo as the critical platform.

“AI is transforming every industry, and its most profound impact will be in life sciences,” said Jensen Huang, founder and CEO of NVIDIA. “NVIDIA and Lilly are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made.”

“For nearly 150 years, we’ve been working to bring life-changing medicines to patients,” said David A.

원문: NVIDIA News — "NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI" (2026-02-27) 공식 원문: https://nvidianews.nvidia.com/news/nvidia-and-lilly-announce-co-innovation-lab-to-reinvent-drug-discovery-in-the-age-of-ai

NVIDIA News
04 Read next 전체 보기 →
Living

오픈소스 취약점 스캔 서비스 OSS Scanner 무료 출시

Living

메타, 싱가포르 장애인을 위해 AI 안경 1000개 기부

Living

삼성전자 2026년 3분기 영업이익 107.4조 원 발표

← Previous엔비디아, Lumentum에 20억 달러 투자해 광학기술 협력 Next →인도 AI 시장, 2031년 $32B까지 성장 전망

바로가기 등록하시면, 더 쉽게 찾아보실 수 있습니다.